Dental Implants in Folsom: What 2025 Research Found About Osteoporosis Medication and Implant Safety
Millions of people take medication for osteoporosis, which weakens bones and raises fracture risk. The most common osteoporosis medicines are called antiresorptives, and the best-known group within them is the bisphosphonates. If you take one of these medicines and you are missing teeth, you may have heard that dental implants could be risky. A 2025 systematic review and meta-analysis looked at the actual evidence, and its findings are more reassuring than many patients expect. Here is what it found, and what it means for patients considering dental implants in Folsom.
What Are Antiresorptive Medications?
Antiresorptives are medicines that slow down the natural process by which bone is broken down and rebuilt. In osteoporosis, bone is broken down faster than it is rebuilt, so bones become thin and fragile. Antiresorptives tip the balance back, helping bones stay stronger and cutting fracture risk.
The most widely prescribed antiresorptives are bisphosphonates, such as alendronate, risedronate, and zoledronic acid, usually taken as a weekly tablet or periodic infusion. Another, denosumab, is injected twice a year. For many people, these medicines are the main protection against a hip or spine fracture — which is why whether they interfere with dental implants needs an answer from real evidence, not worry alone.
What Is MRONJ?
The main concern with antiresorptives and dental treatment is a rare condition called medication-related osteonecrosis of the jaw, usually shortened to MRONJ. Osteonecrosis means bone tissue dies, and in MRONJ the affected bone in the jaw does not heal properly and can become exposed. It can follow a tooth extraction or implant placement, or sometimes happen without any dental procedure at all.
MRONJ is uncommon, and far more common in people who receive high doses of antiresorptives for cancer-related bone disease than in people on the much lower doses used for osteoporosis. Because it can be difficult to treat, dentists take it seriously, and patients on antiresorptives should always tell their dentist about every medication they use.
What the 2025 Review Examined
The 2025 study was a systematic review and meta-analysis carried out to inform the 2024 update of the International Task Force on Osteonecrosis of the Jaw. For the implant-failure analysis, the researchers included 9 studies covering 655 patients taking antiresorptive therapy for osteoporosis. They compared implant failure in patients exposed to antiresorptives with implant failure in patients who were not, and they also gathered data on MRONJ cases after implant placement, drawing on 21 cohorts.
What the Researchers Found
The headline finding is reassuring: among patients taking antiresorptives for osteoporosis, the relative risk of implant failure was 0.82 (95 percent confidence interval 0.52 to 1.28, p-value 0.38) — no clear increase. The authors rated the certainty of this evidence as very low, so the finding is encouraging but the evidence base is still limited.
A sensitivity analysis at the implant level suggested antiresorptives might even reduce implant failure (relative risk 0.53, 95 percent confidence interval 0.34 to 0.81, p-value 0.003, very low certainty) — an interesting signal, not proof of a benefit.
On MRONJ, the researchers identified 186 cases. The pooled rate after implant placement in patients exposed to antiresorptives was 0.5 percent across 21 cohorts — about one in two hundred patients. Bisphosphonates increased MRONJ by about 3 cases per 1,000 patients (adjusted hazard ratio 4.09, 95 percent confidence interval 2.75 to 6.09, p-value less than 0.001, moderate certainty). The risk is real, but low in absolute terms at osteoporosis doses.
What This Means for You
If you take an osteoporosis medicine and you are considering dental implants, this study supports a careful, individualized conversation, not a blanket yes or no. The evidence shows no clear increase in implant failure, and the absolute risk of MRONJ after implant placement was about one in two hundred — a risk worth understanding and planning around, but for many patients not a reason to rule out implants.
What matters is the full picture: which medicine you take, how long you have taken it, and how it is given. Tell your dentist about all of your medications before any dental procedure, and never stop a prescribed medication on your own — stopping an osteoporosis medicine without talking to your doctor can raise your fracture risk. Any decision about pausing a medicine should be made together by you, your dentist, and your physician.
How Your Prosthodontist Plans Implants Safely
At Expert Dental Group, Dr. Leila Nikpour is a prosthodontist in Roseville who plans every implant case with in-house 3D CBCT imaging, so the bone, the bite, and the best implant position are mapped before treatment begins. If you are exploring dental implants in Folsom, bring a full list of your medications to your consultation, including any osteoporosis medicine, so your plan can be built around your whole health picture — reading about dental implants first helps you ask better questions. Dr. Nikpour brings more than 15 years of dentistry experience, has placed 2,500+ dental implants, and completed a one-year implantology fellowship in France.
Visit Expert Dental Group
Expert Dental Group is located at 5070 Foothills Blvd, Suite 2, Roseville, CA 95747. Call (916) 888-1646 to schedule your consultation. Hours: Monday–Friday 9–6, Saturday 9–1.
Frequently Asked Questions
Can I get dental implants if I take osteoporosis medication?
In many cases, yes. A 2025 meta-analysis of 655 patients found no clear increase in implant failure among patients taking antiresorptive therapy for osteoporosis. Your dentist and physician should review your specific medication, dose, and health history together before deciding.
What is MRONJ?
MRONJ stands for medication-related osteonecrosis of the jaw. It is a rare condition in which jawbone exposed to certain medicines does not heal properly and can become exposed. It is uncommon at osteoporosis doses, and the 2025 review estimated a pooled rate of about 0.5 percent after implant placement in patients on antiresorptives.
How high is the risk of MRONJ after a dental implant?
The 2025 review found a pooled MRONJ rate of 0.5 percent after implant placement in patients exposed to antiresorptives, based on 21 cohorts. Bisphosphonates increased MRONJ by about 3 cases per 1,000 patients. The absolute risk is low, but it is real and should be discussed before treatment.
Should I stop my osteoporosis medication before getting implants?
Never stop a prescribed medication without talking to your doctor. Stopping an osteoporosis medicine can raise your fracture risk. Any decision about pausing a medicine around a dental procedure should be made together by you, your dentist, and your physician.
What should I tell my dentist before implant treatment?
Tell your dentist about every medication you take, including osteoporosis medicines, how long you have taken them, and how they are given. Bring a full medication list to your consultation so your implant plan can be built around your complete health picture.
References
Mirza R, et al. Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis. Endocrine Practice. 2025;31(9):1189–1196. doi: 10.1016/j.eprac.2025.06.003. PMID: 40505730. https://doi.org/10.1016/j.eprac.2025.06.003 — https://pubmed.ncbi.nlm.nih.gov/40505730/
